Home › Companies › Actinium Pharmaceuticals, Inc. › 2025-2026
At Actinium Pharmaceuticals, Inc.'s shareholder meeting held November 26, 2025, in the 2025-2026 proxy season, 54 asset managers reported how they voted in their SEC Form N-PX filings, covering 165 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers; — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Actinium Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on November 26, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Actinium Pharmaceuticals, Inc.’s Form 8-K, filed November 26, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of November 26, 2025: 4 items on Actinium Pharmaceuticals, Inc.’s Form 8-K, filed November 26, 2025: 4 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Actinium Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Actinium Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed November 26, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Ajit S. Shetty | 5,032,369 | -- | -- | 1,234,852 | 9,354,877 | 80% | Not verified | — |
| Elect Director: June S. Almenoff | 5,284,503 | -- | -- | 982,719 | 9,354,877 | 84% | Not verified | — |
| 2. To ratify the appointment of CBIZ as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 13,724,478 | 1,537,998 | 232,097 | -- | -- | 90% | Not verified | — |
| 3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers | 4,481,875 | 1,541,460 | 243,885 | -- | 9,354,877 | 74% | Not verified | — |
Source: Actinium Pharmaceuticals, Inc., Form 8-K, filed with the SEC on November 26, 2025 — read the filing on EDGAR.
Each item below shows how the 54 asset managers that disclosed a Actinium Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Actinium Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
99.7% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To elect each of Ajit Shetty and June S. Almenoff as a Class III director to serve for a three-year term that expires at the 2028 Annual Meeting of Stockholders, or until his or her successor is elected and qualified or until his or her earlier resignation or removal: Ajit Shetty
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,222,751 | 0 | 0 | 0 | For |
| Fidelity | 200,515 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 40,000 | 0 | 0 | 0 | For |
| Equitable | 5,849 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 3,257 | Withhold |
| Blackstone Alternative Investment Funds | 3,114 | 0 | 0 | 0 | For |
| BlackRock | 717 | 0 | 0 | 0 | For |
Fund voting reports, all 7 managers: 1,472,946 for, 3,257 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Keel Point, LLC | 42,294 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 42,294 for.
Combines 2 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To elect each of Ajit Shetty and June S. Almenoff as a Class III director to serve for a three-year term that expires at the 2028 Annual Meeting of Stockholders, or until his or her successor is elected and qualified or until his or her earlier resignation or removal: June S. Almenoff
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,222,751 | 0 | 0 | 0 | For |
| Fidelity | 200,515 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 40,000 | 0 | 0 | 0 | For |
| Equitable | 5,849 | 0 | 0 | 0 | For |
| Jackson National | 3,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 3,114 | 0 | 0 | 0 | For |
| BlackRock | 717 | 0 | 0 | 0 | For |
Fund voting reports, all 7 managers: 1,476,203 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Keel Point, LLC | 42,294 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 42,294 for.
Combines 7 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers;
Actinium Pharmaceuticals, Inc.’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 4,481,875 for, 1,541,460 against, per its Form 8-K filed November 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,222,751 | 0 | 0 | 0 | For |
| Fidelity | 200,515 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 40,000 | 0 | 0 | 0 | For |
| Equitable | 5,849 | 0 | 0 | 0 | For |
| Jackson National | 0 | 3,257 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 3,114 | 0 | 0 | 0 | For |
| BlackRock | 717 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 140 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 1,473,086 for, 3,257 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ACADIAN ASSET MANAGEMENT LLC | 447,429 | 0 | 0 | 0 | For |
| BlackRock | 266,365 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 264,219 | 0 | 0 | 0 | For |
| Two Sigma | 181,009 | 0 | 0 | 0 | For |
| Citadel | 171,093 | 0 | 0 | 0 | For |
| Gen-Wealth Partners Inc | 109,381 | 0 | 0 | 0 | For |
| State Street | 83,796 | 0 | 0 | 0 | For |
| Renaissance | 54,180 | 0 | 0 | 0 | For |
| Keel Point, LLC | 42,294 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 40,000 | 0 | 0 | 0 | For |
| Callan Family Office, LLC | 23,603 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 22,364 | 0 | 0 | 0 | For |
| MML INVESTORS SERVICES, LLC | 20,432 | 0 | 0 | 0 | For |
| WELLS FARGO CLEARING SERVICES, LLC | 19,100 | 0 | 0 | 0 | For |
| Fidelity | 18,996 | 0 | 0 | 0 | For |
| Vanguard | 17,786 | 0 | 0 | 0 | For |
| Northern Trust | 17,195 | 0 | 0 | 0 | For |
| Dimensional | 0 | 8,553 | 0 | 0 | Against |
| STIFEL NICOLAUS & CO INC \MO\ | 6,000 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 5,422 | 0 | 0 | 0 | For |
| ROCKEFELLER FINANCIAL LLC | 4,500 | 0 | 0 | 0 | For |
| ENVESTNET ASSET MANAGEMENT INC | 4,087 | 0 | 0 | 0 | For |
| DE Shaw | 4,034 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 3,275 | 0 | 0 | 0 | For |
| Point72 | 2,259 | 0 | 0 | 0 | For |
Institutional-manager reports, all 48 managers: 1,841,317 for, 9,511 against, 1,743 not voted. Showing the 25 largest; every one is in the interactive database (link above).
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE FREQUENCY OF HOLDING FUTURE ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Jackson National | 0 | 0 | 0 | 0 | -- |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 8 managers: 1,473,086 1 year, 3,257 3 year.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ACADIAN ASSET MANAGEMENT LLC | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| Gen-Wealth Partners Inc | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Renaissance | 0 | 0 | 0 | 0 | -- |
| Keel Point, LLC | 42,294 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Callan Family Office, LLC | 0 | 0 | 0 | 0 | -- |
| MARSHALL WACE, LLP | 0 | 0 | 0 | 0 | -- |
| MML INVESTORS SERVICES, LLC | 0 | 0 | 0 | 0 | -- |
| WELLS FARGO CLEARING SERVICES, LLC | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 0 | 0 | 0 | -- |
| MELLON INVESTMENTS Corp | 0 | 0 | 0 | 0 | -- |
| ROCKEFELLER FINANCIAL LLC | 0 | 0 | 0 | 0 | -- |
| ENVESTNET ASSET MANAGEMENT INC | 0 | 0 | 0 | 0 | -- |
| DE Shaw | 0 | 0 | 0 | 0 | -- |
| Fisher Asset Management, LLC | 0 | 0 | 0 | 0 | -- |
| Point72 | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 44 managers: 42,294 for, 855 not voted, 1,624,700 1 year, 180,408 3 year. Showing the 25 largest; every one is in the interactive database (link above).
90% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF CBIZ CPAS P.C., AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
Actinium Pharmaceuticals, Inc.’s own tally for this item (“2. To ratify the appointment of CBIZ as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 13,724,478 for, 1,537,998 against, per its Form 8-K filed November 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,222,751 | 0 | 0 | 0 | For |
| Fidelity | 200,515 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 40,000 | 0 | 0 | 0 | For |
| Equitable | 5,849 | 0 | 0 | 0 | For |
| Jackson National | 3,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 3,114 | 0 | 0 | 0 | For |
| BlackRock | 717 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 140 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 1,476,343 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Keel Point, LLC | 42,294 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 42,294 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 31,195,891 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.92% |
| 2 | Fidelity | 0.64% |
| 3 | BRIDGEWAY FUNDS INC | 0.13% |
| 4 | Equitable | 0.02% |
| 5 | Jackson National | 0.01% |
| 6 | Blackstone Alternative Investment Funds | <0.01% |
| 7 | BlackRock | <0.01% |
| 8 | Advisors' Inner Circle Fund III | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ACADIAN ASSET MANAGEMENT LLC | 1.43% |
| 2 | BlackRock | 0.85% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 0.85% |
| 4 | Two Sigma | 0.58% |
| 5 | Citadel | 0.55% |
| 6 | Gen-Wealth Partners Inc | 0.35% |
| 7 | State Street | 0.27% |
| 8 | Renaissance | 0.17% |
| 9 | Keel Point, LLC | 0.14% |
| 10 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.13% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 4.56% | 13F |
| Millennium Management | 1.81% | 13F |
| Renaissance Technologies | 1.51% | 13F |
| BlackRock | 1.19% | 13F |
| Two Sigma | 1.08% | 13F |
| Geode Capital | 1.08% | 13F |
| Sandesh Seth | 0.81% | DEF14A |
| State Street | 0.40% | 13F |
| Citadel Advisors | 0.32% | 13F |
| Northern Trust | 0.24% | 13F |
Percentages above are of 31,195,891 shares outstanding, as reported by Actinium Pharmaceuticals, Inc. on its Form 10-Q dated November 14, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Actinium Pharmaceuticals, Inc.’s 10-Q dated November 14, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Actinium Pharmaceuticals, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Actinium Pharmaceuticals (ATNM) 2025 Annual Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/actinium-pharmaceuticals-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.